Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Gains from Sales and Divestitures (2024 - 2025)

Maze Therapeutics has reported Gains from Sales and Divestitures over the past 2 years, most recently at $1.1 million for Q4 2025.

  • Quarterly Gains from Sales and Divestitures changed 0.0% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $1.1 million for FY2025, 0.0% changed from the prior year.
  • Gains from Sales and Divestitures was $1.1 million for Q4 2025 at Maze Therapeutics, roughly flat from $1.1 million in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $1.1 million in Q4 2024 and troughed at $1.1 million in Q4 2024.